Recent KZR News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 09:05:27 PM
- Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis • Business Wire • 10/04/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:36:09 PM
- Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients • Business Wire • 09/30/2024 12:30:00 PM
- Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/04/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:05:42 PM
- Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/13/2024 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 09:41:02 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 07/10/2024 08:01:00 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 06/07/2024 09:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:30:33 PM
- Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:04:53 PM
- Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/09/2024 08:01:00 PM
- Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 05/06/2024 08:05:00 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/08/2024 08:01:00 PM
- Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update • Business Wire • 03/14/2024 08:01:00 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 03/08/2024 09:05:00 PM
- Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 09:01:00 PM
- Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis • Business Wire • 02/26/2024 11:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:50:01 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 09:56:20 PM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM